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Abstract 
To identify molecular markers with predictive value for the progression of superficial bladder cancer we used the 
differential hybridization analysis approach. Since primary tumor material is heterogeneously composed of subpopulations 
that are poorly characterized, we used in this study a rat progression model system that phenotypically and cytogenetically 
resembles human superficial bladder cancer. In the differential hybridization analysis we compared the mRNA populations 
of low and high metastatic tumor lines. We observed an overexpression f ferritin Heavy chain (ferritin H) in the tumor line 
with the lower metastatic apacity and better differentiated phenotype. The exact clinical relevance for the differential 
expression of ferritin H in human bladder cancer emains to be determined. 
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1. Introduction 
An important issue in the management of superfi- 
cial transitional cell carcinoma (TCC) of the bladder 
is to identify those patients that are at risk for pro- 
gression to invasive disease. Since primary tumor 
material is usually heterogeneously composed of sub 
populations that are poorly characterized, it is not 
suitable to identify TCC progression markers. The 
identification of such parameters requires a tumor 
model system in which the different stages of tumor 
progression are represented. 
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In this study a rat bladder tumor model system 
(RBT) is used that phenotypically and cytogenetically 
resembles human superficial TCC [1]. Two sponta- 
neously arisen bladder tumors (in ACI rats) RBT 323 
and RBT 157, were serially transplanted. In the fifth 
transplant generation the RBT 323 becomes metastatic 
to the lungs in more than 90% of animals. The 
metastatic ability of the RBT157 tumor changes from 
low to intermediate (50% of the rat have lung metas- 
tases) in the fourth passage. The tumor doubling time 
of the RBT 323 tumor decreased from 13 days to 
3.5-4 days, while the tumor doubling time of the 
RBT 157 tumor remained almost unchanged. Both 
tumor lines initially resembled grade II TCC. How- 
ever, while the histological pattern of the RBT 157 
remained essentially unchanged, the RBT 323 tumor 
progressed to a grade III tumor in the third passage 
[1]. In order to identify genes that are associated with 
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the progression of superficial bladder cancer we ap- 
plied the technique of differential hybridization anal- 
ysis to compare the mRNA levels of the RBT 323 
with the RBT 157 line, two lines that differ in their 
metastatic capacity. The cDNA clones that detected 
differentially expressed genes were further evaluated 
for their relationship to the metastatic phenotype by 
means of Northern blot analyses. The cDNA clones 
of interest were sequenced and the resulting nu- 
cleotide sequences were compared to nucleotide 
database to search for homology with known genes. 
2. Materials and methods 
2.1. Tumor specimens 
Tumor material from a rat bladder tumor model 
system (RBT) [1] was used in this study (Table 1). 
Transplant passage #10 of the highly metastatic line 
RBT 323 and passage #1 of the moderate metastatic 
line RBT 157 were used for the differential hy- 
Table 1 
Growth characteristics of rat bladder tumor lines 
Tumor passage Tumor doubling time a Metastases b
RBT323 ND 0/1 
Passage l ND 0/6 
Passage 2 13.4 (1.4) 0/8 
Passage 3 11.8 (1.2) 1/10 
Passage 4 5.9 (1.0) 0/9 
Passage 5 5.7 (0.3) 3/7 
Passage 6 4.4 (0.1) 11 / 13 
Passage 8 3.8 (0.2) 15/15 
Passage 10 3.7 (0.2) 9/9 
Passage 12 4.2 (0.3) 19/22 
Passage 13 3.3 (0.3) 6/6 
Passage 15 4.3 (0.3) 5/6 
Passage 16 4.0 (0.3) 6/6 
RBT 157 ND 0/1 
Passage 1 11.2 (0.8) 0/4 
Passage 2 ND 1/7 
Passage 3 10.5 (1.1) 2/9 
Passage 4 8.2 (0.3) 5/8 
Passage 6 9.5 (1.8) 2/6 
a Tumor doubling time in days, SEM in brackets (ND, not 
determined). 
b Number of rats with lung metastases/total number of rats 
implanted with respective tumor passage. 
bridization experiments. In order to check the rele- 
vance of the selected clones passages 1, 2, 8, 9, 15 
and 16 of the RBT 323 line and passage 1 and 6 of 
the RBT 157 line were used. 
2.2. Construction of cDNA libraries 
A directionally cloned cDNA library was con- 
structed using polyadenylated cytoplasmic RNA from 
the highly metastatic RBT323 line, passage #10. 
Poly(A + )RNA (5 /xg) was fractionated from total 
RNA by oligo(dT)-cellulose chromatography and to- 
tal RNA was isolated using the lithium chloride/urea 
procedure [2]. First strand cDNA was synthesized by 
using an oligo(dT) primer-adaptor (Promega) contain- 
ing a NOT-1 site 5' to the oligo(dT) tail. Second 
strand cDNA synthesis was performed using the pro- 
cedures described by Gubler and Hofman [3]. The 
cDNA was blunt ended by using T4-DNA poly- 
merase (10 U). After purification using micro collo- 
dion bags (Sartorius GmbH), EcoR1 linkers (1 /xg, 
Stratagene) were ligated to the blunt ended cDNA by 
means of T4-DNA ligase, followed by digestion with 
NOT-t and EcoR1 restriction endonucleases. The 
digested linkers were separated from the cDNA by 
means of PurElute TM agarose gel electrophoresis (In- 
vitrogen) and the cDNAs with the desired size range 
(0.5-10 kb) were isolated from the agarose. Electroe- 
lution of the cDNA from the agarose was performed 
using the Geneluter TM electroelution system (|nvitro- 
gen). Subsequently the ds cDNA was ligated in the 
Lambda Zap-II cloning vector (Stratagene), inserted 
into the phage particles using Promega Packagene 
Lambda DNA Packaging System and transformed to
XL-1 Blue E. coli bacteria. 
2.3. Differential screening of the cDNA library 
For the differential screening of the RBT 323/10 
cDNA library, 36000 recombinant phages were 
plated. After overnight incubation, 4 replicas of each 
plate were taken on nitrocellulose by incubation dur- 
ing 1, 3, 10 and 30 min, respectively. The filters were 
next lysed according to Sambrook et al. [4]. Hy- 
bridization was performed according to Hanahan and 
Meselson [5] in 40% formamide at 42°C during 60 
hours. For the differential screening, probes represen- 
tative for the RBT 323/pass •10 and RBT 157/pass 
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• 1 mRNA populations were prepared by random 
prime labeling [6] of first strand cDNA. For hy- 
bridization of the filters, 1 • 10  6 dpm/ml hybridiza- 
tion solution was used. The replicas 1 and 10 min 
were hybridized with probe derived from the RBT 
157/pass.1 and the replicas 3 and 30 rain were 
hybridized with probe derived from the RBT 
323/pass.10. The blots were washed according to 
Hanahan and Meselson [5]. The filters were exposed 
for autoradiography during three days. Extensive 
comparison of the autoradiograms resulted in selec- 
tion of differentially expressed clones. 
2.4. Phagemid isolation 
Putative differential expressed cDNA clones were 
purified and phagemids were isolated according to 
the Stratagene protocol. 
2.5. Northern blot analysis 
For the northern blot analysis, l0 ~g of total RNA 
was glyoxylated, size fractionated on 1% agarose gels 
and transferred to Hybond-N + nylon membranes 
(Amersham). Probes were made of the differentially 
expressed cDNA clones, obtained from small scale 
plasmid isolations or of purified inserts of the cDNA 
clones, by random prime labeling reactions [6]. Hy- 
bridization experiments were performed according to 
Church and Gilbert [7]. 
2.6. Sequence analysis and computer analysis 
Sequence analysis was performed with the Seque- 
nase Version 2.0 System (United States Biochemical). 
M13 and reverse primers were used allowing se- 
quence analysis from both ends of the clones. Corn- 
Fig. 1. Differential screening ofthe RBT 323/10 cDNA library. Replicas were hybridized tocDNA probes prepared using poly-A+-RNA 
from the RBT 157/1 line (a + c) or from the RBT 323/10 line (b + d). The arrows indicate the three most significant differentially 
expressed cDNA clones. 
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puter assisted comparison studies of the sequences 
were performed with the EMBL and Genbank nu- 
cleotide sequence databases. 
3. Resu l ts  
pressed; 16 overexpressed in the RBT 323 line and 6 
overexpressed in the RBT 157 line. These 22 selected 
cDNA clones were further evaluated using Northern 
blots containing 10 /xg of RBT 157/1, RBT 323/1 
and RBT 323/10 RNA. The expression pattern of 
the most significant clone pV13 is shown in Fig. 2A. 
3.1. Differential screening 3.2. Expression pattern of pV13 
A cDNA library was constructed from the mRNA 
of the highly metastatic line RBT 323/passage 10. 
The complexity of the library was 4.3 • 105 recombi- 
nant clones and 36 000 recombinant phages from the 
primary library were plated. Replica filters were dif- 
ferentially screened using radioactively abeled cDNA 
probes derived from poly-A+RNA of the RBT 
323/pass.10 (high metastatic) and the RBT 
157/pass.1 (low metastatic). Extensive comparison 
of the resulting autoradiograms (Fig. 1) revealed 22 
cDNA clones that seemed to be differentially ex- 
Clone pV13, is clearly overexpressed in RBT 
157/1, the line with the lowest metastatic apacity. 
pV13 detects a single transcript of approx. 1.1 kb 
(Fig. 2A). The correlation of clone pV13 expression 
with metastatic capacity was further studied by means 
of Northern blot analysis of more passages of the rat 
progression model (Fig. 2B). The passages 1 and 6 of 
the RBT 157 line, with the moderate metastatic a- 
pacity, show both an higher expression level of pV 13 
compared to the tested passages of the RBT 323 line, 
with the high metastatic apacity. As a control we 
(A) ~) 
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Fig. 2. 10 /.Lg of total RNA was glyoxylated, size fractioned on 1% agarose gels and transferred toHybond-N +nylon membranes. A. 
Secondary screening of the selected cDNA clone pVl3 on the passages RBT 157/1 (1), RBT 323/1 (2) and RBT 323/10 (3). Probe 
pV13 was made of the differentially expressed cDNA clone by random prime labelling reactions. B. Correlation of clone pV13 with 
metastatic phenotype. The probe was made, using the isolated insert of cDNA clone pV13, by random labelling reaction, rRNA was used 
as an internal control for the amount of RNA loaded (shown in lower panel (B)). 
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studied the expression of pV13 in Dunning R-3327 
rat prostatic tumors [8] and in normal rat prostate (in 
normal bladder insufficient RNA was isolated from 
the tiny layers of urothelium). The higher expression 
of pV 13 in the sublines with lower metastatic capac- 
ity, as seen for the bladder tumor model system, was 
confirmed and in normal rat prostate no expression of 
pV13 was observed (data not shown). 
3.3. DNA sequence analysis of pV13 
To obtain further information on the cDNA clone, 
the nucleotide sequences were determined using the 
Sequenase Version 2.0 sequence system. Computer- 
assisted comparison of the resulting nucleotide se- 
quences with the EMBL and Gen bank nucleotide 
sequence databases revealed that pV13 is highly ho- 
mologous to the Rat Ferritin Heavy chain gene (97%) 
[9] and the Mouse Ferritin Heavy chain (94%) [10]. 
4. Discussion 
In search of new molecular markers with predic- 
tive value for the progression of superficial TCC, we 
compared two different tumor lines of a rat TCC 
model system at the level of gene expression using 
differential hybridization analysis. We observed an 
overexpression of ferritin H in the RBT 157 tumor 
line which displays the lowest metastatic apacity 
and the best differentiated phenotype. 
Ferritin H combines with the ferritin L subunit o 
form the iron storage protein ferritin [11]. Ferritin 
H-rich molecules take up and release iron more read- 
ily than L-rich molecules, that are more suited for 
long-term storage [12]. A relationship between fer- 
ritin and cancer has been proposed, since serum 
ferritin is frequently elevated in patients with cancer 
[13,14]. Some neoplastic ells also exhibit a remark- 
ably altered ferritin subunit composition (i.e enrich- 
ment for the heavy chain subunit) as compared to 
their normal counterparts [ 15,16]. A direct association 
between oncogenic transformation and ferritin syn- 
thesis has been suggested, since the adenovirus E1A 
oncogene specifically represses ferritin H expression 
[17]. The observed down regulation of ferritin H 
expression in the more malignant umor line RBT 
323 is in concordance with this observation. The 
correlation between ferritin H expression and a num- 
ber of differentiation processes shown by others 
[18,19], is corroborated in this study by the overex- 
pression of ferritin H in the better differentiated 
tumor line RBT 157. In smooth muscle cells it is 
proposed that cAMP promotes ferritin H expression 
resulting in both growth arrest and an enhanced 
differentiated phenotype [20]. 
The exact biological consequences of altered fer- 
ritin subunit composition are not well understood. It
may result in modulation of the iron binding capacity 
of ferritin and ultimately, the regulatory pools of free 
iron [21,11 ]. An enrichment for the ferritin H subunit 
leads to more efficient iron detoxification and cellular 
protection against free radical formation [22]. An- 
other mechanism underlying the regulation of ferritin 
expression has been extensively studied and is ex- 
erted posttranscriptionally by specific mRNA-protein 
interaction between the iron-regulating protein (IRE- 
BP) and Iron-Responsive Elements (IREs) contained 
in the 5'untranslated region of ferritin. Iron inacti- 
vates the cytoplasmic IRE-BP, thereby preventing its 
binding to the IRE and consequently derepressing 
ferritin translation [23]. 
It should be emphasized that the mechanisms un- 
derlying the altered subunit composition of ferritin in 
neoplastic ells are not elucidated. Ferritin H is lo- 
cated on human chromosome 11 [24], near l lq13 
[25], a region that is sometimes amplified in bladder 
cancer [26]. We have determined that the ferritin H 
gene is not within the amplicon on 1 lq13 (data not 
shown). 
Cytogenetic analysis of the RBT lines showed that 
both of the independently arisen tumors exhibit loss 
of chromosome 5 [1]. Rat chromosome 5 is syntenic 
to the major portion of human chromosome 9 (p23- 
qter) a chromosome that is commonly lost in human 
TCC. The more aggressive subline RBT 323 has 
considerably more cytogenetic hanges compared to 
RBT 157. Due to the fact that the comparative ge- 
nomic map of human and rat is rather restricted [27] 
it is difficult to speculate about the genes potentially 
relevant o the observed cytogenetic changes. 
Our findings show a correlation of ferritin H over- 
expression with lower metastatic apacity and better 
differentiated phenotype in a rat bladder tumor model 
system. We are currently investigating the value of 
differential expression of ferritin H as a prognostic 
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marker in human bladder cancer using quantitative 
comparative Polymerase Chain Reaction. 
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